Marshall Edwards elects Robert Mass CMO
This article was originally published in Scrip
Marshall Edwards, an oncology company, has appointed Dr Robert Mass chief medical officer. Dr Mass joins the companyafter over a decade at Genentech, where he most recently served as head of medical affairs and played a leading role in the clinical development of drugs such as Herceptin (trastuzumab), Tarceva (erlotinib) and Avastin (bevacizumab).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.